不同药物联合卡络磺钠对支气管扩张伴咯血中的临床疗效分析

Clinical Effect of Different Drugs Combined with Kalo Sodium in Treatment of Bronchiectasis with Hemoptysis

目的:分析不同药物联合卡络磺钠对支气管扩张伴咯血中的临床疗效。方法:回顾性分析2013年1月至2016年12月我院收治的支气管扩张伴咯血患者,将接受酚妥拉明联合卡络磺钠治疗的30例患者视为观察组,垂体后叶素联合卡络磺钠治疗的30例患者视为对照组。比较两组患者临床疗效、平均出血量和出血时间及不良反应的发生情况。结果:治疗后,观察组和对照组的临床总有效率比较差异无统计学意(83.33%vs.86.67%,P>0.05)。观察组和对照组的平均出血量(161.34±34.51vs.155.22±34.23)、出血时间(5.27±0.52vs.5.38±0.51)d)比较差异无统计学意义(P>0.05)。观察组总的不良反应率显著低于对照组(20.00%vs..50.00%P<0.05)。结论:酚妥拉明与垂体后叶素联合卡络磺钠治疗支气管扩张伴咯血临床疗效相当,但酚妥拉明联合卡络磺钠治疗的安全性更高。

Objective： To analyze the clinical effect of different drugs combined with kalo sodium in treatment of bronchiectasis with hemoptysis. Methods： A retrospective study was conducted on 60 patients with bronchiectasis with hemoptysis from January 2013 to December 2016. The 30 cases of patients were treated with phentolamine combined with cardosulfan sodium as the observation group. 30 cases of patients were treated with pituitrin combined with cardosulfan sodium as the control group. Comparison of two groups of patients with clinical efficacy,the average amount of bleeding and bleeding time,adverse reaction rate. Results：After treatment,there was no statistically significant difference in the total effective rate between the observation group and the control group（ 83.33% vs. 86.67%,P〉0.05）. The average blood loss（ 161.34±34.51 vs.155.22±34.23） and bleeding time（ 5.27±0.52 vs. 5.38±0.51） d in the observation and control groups were not statistically different（ P〉0.05）.The total adverse reaction rate of the observation group was significantly lower than that of the control group（ 20.00% vs.. 50.00% P〈0.05）. Conclusion： Phentolamine and pituitrin combined with cardulfonated sodium in the bronchiectasis with hemoptysis,can produce a good clinical efficacy,but phentolamine combined with cardulfonated sodium treatment of bronchiectasis with hemoptysis,which he reaction rate is low.